Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 2,005 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Discrete Clear all

Conditions: High Risk for Postoperative Cardiovascular Events
Interventions: endothelial function testing; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 50 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Aortic Stenosis, Brain Infarction, Cerebrovascular Accident, Stroke
Interventions: Embol-X Embolic Protection Device, CardioGard Cannula; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 60 Years and older
Enrollment: 383 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 14
States / cities: Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 11 more

Conditions: Pediatric Cancer, Pediatric ALL, Pediatric Brain Tumor, Attention Difficulties, Cognitive Deficit in Attention
Interventions: EndeavorRx, Control video game; Device · Other
Lead sponsor: Children's National Research Institute; Other
Eligibility: 8 Years to 16 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Human Volunteers
Interventions: BMN 673; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Gardasil Vaccine, Stem Cell Transplant, Immunogenicity
Interventions: Gardasil; Biological
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Tobacco Use Cessation, Tobacco Cessation, Tobacco Use Disorder, Tobacco Dependence, Tobacco-Use Disorder, Virus, Human Immunodeficiency
Interventions: Web-Based Tailored Smoking Cessation Intervention, Standard of Care; Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Obesity, Critical Illness
Interventions: Imipenem/Cilastatin/Relebactam 1.25g; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Discogenic Pain
Interventions: High yield pure PRP, Placebo, ProPlaz PPC; Device · Other
Lead sponsor: Neurological Associates of West Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 7
States / cities: Campbell, California • Santa Monica, California • Peachtree City, Georgia + 2 more

Conditions: Mastectomy; Lymphedema
Interventions: Cryoneurolysis, Sham Comparator; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 5
States / cities: Los Angeles, California • San Diego, California • Gainesville, Florida + 2 more

Conditions: Autism
Interventions: Early Start Denver Model (ESDM), Early Intensive Behavioral Intervention (EIBI); Behavioral
Lead sponsor: University of California, Davis; Other
Eligibility: 12 Months and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Diabetes (DM)
Interventions: Exendin-9 is a 30 amino acid peptide that is an established competitive antagonist of the GLP-1 receptor. Subjects will receive exendin-9 by intravenous infusion at a rate of 600 pmol/kg/min, Dexamethasone, Dextrose 20% solution; Drug
Lead sponsor: David D'Alessio, M.D.; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cardiac Catheter Ablation, Atrial Flutter, Cardiac Arrhythmias
Interventions: Data Collection During Atrial Flutter Ablation; Other
Lead sponsor: David B. De Lurgio; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Healthy Volunteers
Interventions: VRG50635, Placebo; Drug
Lead sponsor: Verge Genomics; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Insomnia Disorder
Interventions: ACT-541468, Placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 65 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 5
States / cities: Brandon, Florida • Chicago, Illinois • Las Vegas, Nevada + 2 more

Conditions: HIV Infections
Interventions: HST-NEETs; Biological
Lead sponsor: Catherine Bollard; Other
Eligibility: 18 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Washington D.C., District of Columbia

Conditions: Weight Prejudice
Interventions: Numerical label, Interpretive text-only label, Interpretive magnifying glass icon label, Separated interpretive magnifying glass icon label; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 55 Years
Enrollment: 3,306 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Idiopathic Hyperbilirubinemia, Neonatal Hyperbilirubinemia, Prematurity
Interventions: Phototherapy, glycerin suppository; Procedure · Drug
Lead sponsor: University of Rochester; Other
Eligibility: 30 Weeks to 35 Weeks
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Leukemia
Interventions: Dose Level 1, Dose Level 2, Dose Level 3; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2010
U.S. locations: 3
States / cities: Houston, Texas

Conditions: Healthy Subject, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: Cardiopulmonary Exercise Testing, Magnetic Resonance Imaging; Other · Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Healthy
Interventions: MK-8527, CBZ; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: HIV Infection
Interventions: Abacavir/Lamivudine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 178
States / cities: Montgomery, Alabama • Glendale, Arizona • Phoenix, Arizona + 123 more

Conditions: Overweight and Obesity, Eating Disorders
Interventions: Project Health, Response and Attention Training, The Weight of the Nation; Behavioral · Other
Lead sponsor: Oregon Research Institute; Other
Eligibility: 17 Years to 20 Years
Enrollment: 238 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 2
States / cities: Stanford, California • Springfield, Oregon

Conditions: Exercise, Central Blood Pressure
Interventions: Aerobic Interval Exercise, Continuous exercise; Other
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Physical Activity, Family Communication, Parenting Behavior
Interventions: Physical Activity Promotion, Healthy Eating; Behavioral
Lead sponsor: San Diego State University; Other
Eligibility: 8 Years to 65 Years · Female only
Enrollment: 432 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: San Diego, California

Search by objective public record fields.

Patients Undergoing Major Cancer Surgery: Incidence and Predictive Value for Postoperative Cardiac Events

Neuroprotection in Patients Undergoing Aortic Valve Replacement

Feasibility/Acceptability of Attentional-Control Training in Survivors

Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers

Gardasil Vaccination in Post Stem Cell Transplant Patients

Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV

Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU Patients

Safety and Efficacy of PRP for Treatment of Disc Pain

Ultrasound-Guided Percutaneous Cryoneurolysis to Treat Postoperative Pain After Mastectomy

Examining the Effectiveness of the Early Start Denver Model in Community Programs Serving Young Autism

Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance.

Determination of Catheter Contact by Evaluation of Microelectrode Near-Field Signals

A Study of VRG50635 in Healthy Volunteers

Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder

HIV-1 Specific T -Cells (HST-NEETs) for HIV-Infected Individuals

Impact of Front-of-package Labels on Weight Bias Among Latines

Glycerin Suppositories to Reduce Jaundice in Premature Infants

Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine

MRI and Cardio-Pulmonary Exercise Testing in Evaluating Exercise Intolerance in Patients With Stage I-III Breast Cancer After Chemotherapy Treatment

A Study of Carbamazepine (CBZ) and MK-8527 in Healthy Adult Participants (MK-8527-012)

A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)

Project Health: Enhancing Effectiveness of an Obesity Prevention Program

Central Hemodynamic Exercise Responses Study

A Multi-level Mother-daughter Physical Activity Intervention for Pre- Adolescent Latinas